Adalimumab Clinical Trials (21 Recruiting)

Showing 1–20 of 21 trials

A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease

Crohn's Disease

Takeda100 enrolled54 locationsNCT06045754

Recruiting

Phase 1Phase 2

A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes

Type 1 DiabetesNew Onset

City of Hope Medical Center120 enrolled11 locationsNCT07061574

Recruiting

Phase 2

Early Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis

Immune-related Adverse EventInflammatory Arthritis

Tom Appleton30 enrolled1 locationNCT06037811

Recruiting

Phase 3

A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab

Juvenile Psoriatic Arthritis

AbbVie40 enrolled31 locationsNCT06100744

Recruiting

Phase 2

An Open-Label Study of Effectiveness of Immunomodulatory Medications for Patients With Relapsing Polychondritis

Relapsing Polychondritis

University of Pennsylvania20 enrolled1 locationNCT06941376

Recruiting

Phase 4

Comparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration.

Crohn's Disease

Centre Hospitalier Universitaire de Saint Etienne220 enrolled12 locationsNCT06180382

Recruiting

Phase 2Phase 3

Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation

Skin InflammationAllergic Contact Dermatitis

Wei-Che Ko45 enrolled1 locationNCT05535738

Recruiting

Phase 3

Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response

Rheumatoid Arthritis

University of Nebraska400 enrolled1 locationNCT03414502

Recruiting

Phase 2

Intravitreal Adalimumab Versus Subcutaneous Adalimumab in Non-infectious Uveitis

Uveitis

American University of Beirut Medical Center32 enrolled1 locationNCT02706704

Recruiting

Phase 2

A Randomized, Controlled, Open-label, Multicenter Clinical Trial Comparing the Efficacy and Safety of a Precision Treatment Regimen Based on Clinical-molecular Phenotypes with a Conventional Treatment Regimen in the Treatment of Patients with Active Takayasu's Arteritis

Takayasu Arteritis

Shanghai Zhongshan Hospital124 enrolled1 locationNCT06498089

Recruiting

Phase 4

Filgotinib Effect on Proteomic Profile and Micro-RNA Expression in Patients With Active Rheumatoid Arthritis (RA)

Rheumatoid Arthritis

Universita di Verona30 enrolled1 locationNCT06527534

Recruiting

CHronic Nonbacterial Osteomyelitis International Registry

Chronic Recurrent Multifocal OsteomyelitisChronic Nonbacterial Osteomyelitis

Seattle Children's Hospital2,000 enrolled1 locationNCT04725422

Recruiting

A Study of Adalimumab in Acute Vogt-Koyanagi-Harada Disease

AdalimumabVogt-Koyanagi-Harada Disease

Tianjin Medical University15 enrolled1 locationNCT05590416

Recruiting

Phase 4

Adalimumab Drug Optimisation in Rheumatoid Arthritis Using Therapeutic Drug Monitoring

Rheumatoid Arthritis

Reade Rheumatology Research Institute267 enrolled1 locationNCT04194827

Recruiting

Phase 4

A Trial COmparing staNdard of Care Versus Treat to Target With telemonitoRing and Patient Education in Patients With Ulcerative cOlitis Initiating Adalimumab

Ulcerative Colitis

Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives238 enrolled24 locationsNCT04183608

Recruiting

Phase 4

Control Crohn Safe Trial

Inflammatory Bowel DiseasesCrohn Disease

Maastricht University Medical Center158 enrolled6 locationsNCT03917303

Adalimumab Clinical Trials

Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained Remission

A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease

A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes

Early Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis

A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab

An Open-Label Study of Effectiveness of Immunomodulatory Medications for Patients With Relapsing Polychondritis

Comparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration.

Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation

Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response

Intravitreal Adalimumab Versus Subcutaneous Adalimumab in Non-infectious Uveitis

Baricitinib in the Treatment of Intestinal Behçet's Syndrome

Swiss Dermatology Network of Targeted Therapies (SDNTT)

Effects of TNF Blockade on Human BPH/LUTS

A Randomized, Controlled, Open-label, Multicenter Clinical Trial Comparing the Efficacy and Safety of a Precision Treatment Regimen Based on Clinical-molecular Phenotypes with a Conventional Treatment Regimen in the Treatment of Patients with Active Takayasu's Arteritis

Filgotinib Effect on Proteomic Profile and Micro-RNA Expression in Patients With Active Rheumatoid Arthritis (RA)

CHronic Nonbacterial Osteomyelitis International Registry

A Study of Adalimumab in Acute Vogt-Koyanagi-Harada Disease

Adalimumab Drug Optimisation in Rheumatoid Arthritis Using Therapeutic Drug Monitoring

A Trial COmparing staNdard of Care Versus Treat to Target With telemonitoRing and Patient Education in Patients With Ulcerative cOlitis Initiating Adalimumab

Control Crohn Safe Trial